WT‐1 assists in distinguishing ovarian from uterine serous carcinoma and in distinguishing between serous and endometrioid ovarian carcinoma

Al-Hussaini, Maysa; Stockman, Adam; Foster, Heather; McCluggage, W. Glenn

doi:10.1111/j.1365-2559.2004.01787.x

Cited by 231 publications

(145 citation statements)

References 26 publications

Supporting

Mentioning

134

Contrasting

Unclassified

Order By: Relevance

“…70,[123][124][125][126][127]149 Most tubo-ovarian serous carcinomas exhibit diffuse nuclear positivity with WT1, whereas most uterine serous carcinomas are negative. However, there is some overlap in that a proportion of uterine serous carcinomas are WT1 positive (the percentage has varied between studies) and a small percentage of tubo-ovarian HGSCs are WT1 negative.…”

Section: Distinction Between Ovarian and Uterine Carcinomamentioning

confidence: 99%

“…However, there is some overlap in that a proportion of uterine serous carcinomas are WT1 positive (the percentage has varied between studies) and a small percentage of tubo-ovarian HGSCs are WT1 negative. 70,[123][124][125][126][127] It can be summarised that, although there is some overlap, diffuse WT1 positivity in a serous neoplasm favours a tubo-ovarian origin. In contrast, negative staining is a pointer towards a primary uterine neoplasm.…”

Section: Distinction Between Ovarian and Uterine Carcinomamentioning

confidence: 99%

See 1 more Smart Citation

Data set for reporting of ovary, fallopian tube and primary peritoneal carcinoma: recommendations from the International Collaboration on Cancer Reporting (ICCR)

et al. 2015

View full text Add to dashboard Cite

Section: Distinction Between Ovarian and Uterine Carcinomamentioning

confidence: 99%

Section: Distinction Between Ovarian and Uterine Carcinomamentioning

confidence: 99%

Data set for reporting of ovary, fallopian tube and primary peritoneal carcinoma: recommendations from the International Collaboration on Cancer Reporting (ICCR)

et al. 2015

View full text Add to dashboard Cite

“…This panel traditionally includes WT1 and P53. [5][6][7][8] Accurate identification whether a serous carcinoma originates from the ovary or the endometrium is clinically important as the pattern of tumor spread and the adjuvant therapy may differ, the latter is thought to exhibit a poorer response to platinum-based compounds. 9 Ovarian serous carcinoma characteristically spread intraperitoneally (transcelomic); whereas uterine serous carcinoma spread by both transcelomic and lymphovascular invasion.…”

mentioning

confidence: 99%

Immunophenotyping of serous carcinoma of the female genital tract

et al. 2008

View full text Add to dashboard Cite

To update the data on the expression of 'mesothelioma markers' by serous carcinomas of various sites we have studied cases from ovary (n ¼ 56), endometrium (n ¼ 37), fallopian tube (n ¼ 6), primary peritoneum (n ¼ 5) and cervix (n ¼ 3) using a panel of antibodies (WT1, P53, estrogen receptors, HER2/neu, D2-40, cytokeratin 5/6 and E-cadherin). Ovarian carcinomas demonstrated D2-40 and cytokeratin 5/6 immunoreactivity in 23.2 and 55.4% of cases, respectively. Endometrial carcinomas demonstrated D2-40 and cytokeratin 5/6 immunoreactivity in 43.2 and 37.8% of cases, respectively. D2-40 staining pattern was predominantly focal; however, strong reactivity was identified in 16.2% of endometrial and 10.7% of ovarian carcinomas. HER2/neu oncoprotein overexpression was demonstrated in 7 of 37 (18.9%) uterine serous carcinomas. In contrast, all the serous carcinomas of the other sites were HER2/neu negative. The proportion of positive cases was significantly different in ovarian vs endometrial carcinomas regarding WT1 (P ¼ 0.0458), estrogen receptors (Po0.001) reactivity and HER2/neu overexpression (P ¼ 0.0025). D2-40 and cytokeratin 5/6 are expressed in a considerable proportion of serous carcinomas and should be used cautiously in a 'mesothelioma panel' in situations where serous carcinoma is in the differential diagnosis. HER2/neu was exclusively overexpressed in serous carcinomas of endometrial origin.

show abstract

“…This difference is linked to genetic differences between tumors [38][39][40][41][42][43][44]. In our study we noted that although WT1 was generally positive in SC of fallopian tube, ovarian and peritoneal origin, it didn't show positivity in EEC and ESC.…”

Section: Discussionmentioning

confidence: 52%

Investigation of the Relationship between Malignant Tumors Originated from Peritoneal and Müllerian Epithelium with the Primary and Secondary Müllerian Systems-Immunohistochemical Analysis with Six Markers

Çiftçi¹

2017

Int J Pathol Clin Res

View full text Add to dashboard Cite

The origin of ovarian epithelial tumors is still indistinct. Mülle-rian and coelomic hypothesis are controversial. Recently, there is also a small number of reports that tubo-peritoneal junction may play an important role in the development of tubo-ovarian tumors. Therefore, we aimed to investigate the relationship between tumors originating from Mullerian epithelium and peritoneal mesothelium, in other words primary and secondary Müllerian systems.Seventy malignant tumors originating from the Müllerian epithelium and peritoneal mesothelium were included in the study. Tumors were analysed immunohistochemically for PAX8, WT1, CD56, Ber-EP4, ER and desmin expression. We evaluated the study based on three phases. Firstly, we investigated immunohistochemical stainings of different tumor types in different locations. Secondly, we assessed immunohistochemical characteristics according to their histologicals subtypes, and finally their relationship with primary or secondary Müllerian systems.As a result different immunohistochemical features were detected between both localization and histological types of these tumor groups.Absence of immunoreactivity of PAX8, WT1 and CD56 in endometrial serous carcinomas and, the presence of high immunoreactivity in ovarian and tubal serous carcinomas was considered to be an indicator of different origins of these tumors as primary and secondary Müllerian systems. It also seems possible that tubo-peritoneal junction could be the junction between primary and secondary Müllerian systems and, may play an important role in the development of tubo-ovarian tumors.

show abstract

WT‐1 assists in distinguishing ovarian from uterine serous carcinoma and in distinguishing between serous and endometrioid ovarian carcinoma

Cited by 231 publications

References 26 publications

Data set for reporting of ovary, fallopian tube and primary peritoneal carcinoma: recommendations from the International Collaboration on Cancer Reporting (ICCR)

Data set for reporting of ovary, fallopian tube and primary peritoneal carcinoma: recommendations from the International Collaboration on Cancer Reporting (ICCR)

Immunophenotyping of serous carcinoma of the female genital tract

Investigation of the Relationship between Malignant Tumors Originated from Peritoneal and Müllerian Epithelium with the Primary and Secondary Müllerian Systems-Immunohistochemical Analysis with Six Markers

Contact Info

Product

Resources

About